PDF factsheet
      Z

All mechanism in multiple myeloma for Relapsed or Refractory Multiple Myeloma , clinical trials results

carfilzomib versus placebo (on top lenalidomide and dexamethasone)
ASPIRE, 2015
NCT01080391
carfilzomib with lenalidomide and dexamethasone
versus
lenalidomide and dexamethasone alone
patients with relapsed multiple myelomaopen-label
elotuzumab versus placebo (on top lenalidomide and dexamethasone)
ELOQUENT 2, 2015
NCT01239797
elotuzumab plus lenalidomide and dexamethasone
versus
lenalidomide and dexamethasone alone
patients with Relapsed or Refractory Multiple Myelomaopen-label
Elotuzumab Lenalidomide Dexamethasone versus Lenalidomide + Dexamethasone
ELOQUENT - 2, 0
NCT01239797
Lenalidomide + Dexamethasone +Elotuzumab
versus
Lenalidomide + Dexamethasone
patients with Relapsed or Refractory Multiple Myeloma

  Options


in first

in second

  Filter